Zynerba Pharmaceuticals has started a Phase I clinical programme to study the analgesic effects of ZYN001 for various pain associated disorders.

ZYN001 is a pro-drug of tetrahydrocannabinol (THC) delivered in a drug-adhesive matrix transdermal patch, which is expected to provide consistent and sustained delivery with better tolerability.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, double-blind, placebo-controlled Phase I trial will evaluate single and multiple increasing doses of a variety of ZYN001 formulations to determine an optimal dose for the upcoming Phase II clinical trials in patients with fibromyalgia and neuropathic pain.

Zynerba chairman and CEO Armando Anido said: “The initiation of the ZYN001 clinical programme is an important milestone for the company, as we now have two clinical stage assets, which, upon approval, may address serious unmet medical needs in a variety of disease settings.

“The initiation of the ZYN001 clinical programme is an important milestone for the company, as we now have two clinical stage assets, which, upon approval, may address serious unmet medical needs in a variety of disease settings.”

“We believe that ZYN001 will be important in a number of pain indications, given THC’s known impact on pain transmission and analgesic effect in patients suffering from chronic pain.”

The Phase I trial will investigate the safety, tolerability and pharmacokinetic profile of a single dose of ZYN001, as well as various formulations and patch wear times ranging from 24 hours to seven days in approximately 48 healthy subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Two formulations, based on data from the trial’s single dose portion, will be assessed in several patch applications over a period of 14 days in around 32 healthy subjects.

The primary objective of the trial is to deliver constant levels of THC for optimised efficacy and simultaneously reduce CNS side effects.